Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02480166 · ClinicalTrials.gov registry record · Phase 4
Comparative Efficacy of Fixed-dose Combination Sofosbuvir + Ledipasvir, 8 vs. 12 Weeks in Chronic Hepatitis C Genotype 6
A Phase 4 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 4
- Development phase
- 60
- Enrollment target
NCT02480166: Completed Phase 4 study, sponsored by Stanford University.
NCT02480166 is a Phase 4 study that has completed, run by Stanford University. The registered enrollment target is 60 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02480166, a Phase 4 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 60 participants
- Enrollment target
Study Summary
The primary objectives of this study are to describe the efficacy of: 1. 8-week treatment of SOF/LED for treatment-naïve, non-cirrhotic, HCV genotype 6 2. 12-week treatment of SOF/LED for all other HCV-6 populations
Interventions
- DRUG 8 weeks SOF/LED
- DRUG 12 weeks SOF/LED
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2015-06 |
| Est. Completion | 2016-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02480166
The ClinicalTrials.gov registry entry for NCT02480166 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which 8 weeks SOF/LED is the first listed.
NCT02480166 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02480166 about?
NCT02480166 is a clinical study titled "Comparative Efficacy of Fixed-dose Combination Sofosbuvir + Ledipasvir, 8 vs. 12 Weeks in Chronic Hepatitis C Genotype 6". The primary objectives of this study are to describe the efficacy of: 1. 8-week treatment of SOF/LED for treatment-naïve, non-cirrhotic, HCV genotype 6 2. 12-week treatment of SOF/LED for all other HCV-6 populations
What is the current status of trial NCT02480166?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 60 participants. The study started on 2015-06. Estimated completion is 2016-10.
What interventions are being tested in trial NCT02480166?
The interventions under investigation include: 8 weeks SOF/LED (DRUG), 12 weeks SOF/LED (DRUG).
Who is sponsoring clinical trial NCT02480166?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.